Original Research

Published on 06 Oct 2022

Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors

in Cancer Molecular Targets and Therapeutics

Yin Guan
Yutong Wang
Hongxia Li
Jing Meng
Xia You
Xiaofeng Zhu
Qin Zhang
Tingting Sun
Chuang Qi
Guangyu An

Frontiers in Oncology

doi 10.3389/fonc.2022.986674

5,373 views
5 citations

Original Research

Published on 06 Oct 2022

CAPRIN2 upregulation by LINC00941 promotes nasopharyngeal carcinoma ferroptosis resistance and metastatic colonization through HMGCR

in Cancer Molecular Targets and Therapeutics

Lin Qiu
Rui Zhou
Ling Zhou
Shiping Yang
Jiangxue Wu

Frontiers in Oncology

doi 10.3389/fonc.2022.931749

2,512 views
7 citations

Original Research

Published on 06 Oct 2022

Ferroptosis-related gene signature predicts prognosis in kidney renal papillary cell carcinoma

in Cancer Molecular Targets and Therapeutics

Haiying Yin
Mei Lin
Shaoying Liang
Meijuan Wei
Cuiting Huang
Fengfei Qin
Jiejin Nong
Xianchang Zeng
Caimei Nong
Houji Qin

Frontiers in Oncology

doi 10.3389/fonc.2022.988867

3,150 views
2 citations

Original Research

Published on 05 Oct 2022

Novel compound C150 inhibits pancreatic cancer through induction of ER stress and proteosome assembly

in Cancer Molecular Targets and Therapeutics

Tao Wang
Ping Chen
Scott Weir
Michael Baltezor
Frank J. Schoenen
Qi Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.870473

1,990 views
1 citation

Systematic Review

Published on 03 Oct 2022

Tryptophan 2,3-dioxygenase may be a potential prognostic biomarker and immunotherapy target in cancer: A meta-analysis and bioinformatics analysis

in Cancer Molecular Targets and Therapeutics

Yanyan Hu
Zhongjian Liu
Hui Tang

Frontiers in Oncology

doi 10.3389/fonc.2022.977640

2,678 views
8 citations

Original Research

Published on 03 Oct 2022

Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model

in Cancer Molecular Targets and Therapeutics

Kevin Hollevoet
Debby Thomas
Griet Compernolle
Giles Vermeire
Elien De Smidt
Stéphanie De Vleeschauwer
Trevor R. F. Smith
Paul D. Fisher
Maarten Dewilde
Nick Geukens

Frontiers in Oncology

doi 10.3389/fonc.2022.1017612

2,186 views
5 citations

Original Research

Published on 30 Sep 2022

ITGB5 promotes innate radiation resistance in pancreatic adenocarcinoma by promoting DNA damage repair and the MEK/ERK signaling pathway

in Cancer Molecular Targets and Therapeutics

Xin Wen
Si Chen
Xueting Chen
Hui Qiu
Wei Wang
Nie Zhang
Wanming Liu
Tingting Wang
Xin Ding
Longzhen Zhang

Frontiers in Oncology

doi 10.3389/fonc.2022.887068

2,943 views
9 citations

Review

Published on 29 Sep 2022

Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers – current evidence and future directions

in Cancer Molecular Targets and Therapeutics

Rachel C. T. Lam
David Johnson
Gigi Lam
Michelle L. Y. Li
Joyce W. L. Wong
W. K. Jacky Lam
K. C. Allen Chan
Brigette Ma

Frontiers in Oncology

doi 10.3389/fonc.2022.970242

5,433 views
2 citations

Systematic Review

Published on 29 Sep 2022

The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysis

in Cancer Molecular Targets and Therapeutics

Baibei Li
Huachu Deng
Biao Lei
Leijie Chen
Xinyuan Zhang
Dingran Sha

Frontiers in Oncology

doi 10.3389/fonc.2022.985377

1,957 views
13 citations

Original Research

Published on 29 Sep 2022

MiR-21 and let-7 cooperation in the regulation of lung cancer

in Cancer Molecular Targets and Therapeutics

Jinquan Bai
Zhenzhou Shi
Shuting Wang
Hong Pan
Tong Zhang

Frontiers in Oncology

doi 10.3389/fonc.2022.950043

2,676 views
12 citations

Review

Published on 28 Sep 2022

Ubiquitin-specific peptidase 10, a deubiquitinating enzyme: Assessing its role in tumor prognosis and immune response

in Cancer Molecular Targets and Therapeutics

Ziqi Ye
Jie Chen
Ping Huang
Zixue Xuan
Shuilian Zheng

Frontiers in Oncology

doi 10.3389/fonc.2022.990195

8,556 views
9 citations

Review

Published on 27 Sep 2022

Muramyl dipeptide-based analogs as potential anticancer compounds: Strategies to improve selectivity, biocompatibility, and efficiency

in Cancer Molecular Targets and Therapeutics

Eliza Iwicka
Justyna Hajtuch
Krystyna Dzierzbicka
Iwona Inkielewicz-Stepniak

Frontiers in Oncology

doi 10.3389/fonc.2022.970967

3,081 views
9 citations

Editorial

Published on 27 Sep 2022

Editorial: Targeting DNA repair and the DNA damage response: Beyond the standard PI3 kinase-like kinases

in Cancer Molecular Targets and Therapeutics

John J. Turchi
Katherine S. Pawelczak
Michael Weinfeld
Peter J. McHugh

Frontiers in Oncology

doi 10.3389/fonc.2022.1023500

1,113 views

Review

Published on 27 Sep 2022

AMBRA1 and its role as a target for anticancer therapy

in Cancer Molecular Targets and Therapeutics

Xiang Li
Yuan Lyu
Junqi Li
Xinjun Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.946086

4,902 views
10 citations

Case Report

Published on 26 Sep 2022

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

in Cancer Molecular Targets and Therapeutics

Sha-Sha Wang
Fang Wang
Zhen Zeng
Fang Gao
Huan-Huan Liu
Hui-Na Wang
Yi Hu
Hai-Feng Qin

Frontiers in Oncology

doi 10.3389/fonc.2022.929763

1,620 views
2 citations

Case Report

Published on 23 Sep 2022

Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review

in Cancer Molecular Targets and Therapeutics

Qian Wang
Yong Wang
Xinwei Zhang
Chen Fang
Xiaoying Qian
Yong Li

Frontiers in Oncology

doi 10.3389/fonc.2022.954026

2,793 views
6 citations

Navigation group

Articles

Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors

CAPRIN2 upregulation by LINC00941 promotes nasopharyngeal carcinoma ferroptosis resistance and metastatic colonization through HMGCR

Ferroptosis-related gene signature predicts prognosis in kidney renal papillary cell carcinoma

Novel compound C150 inhibits pancreatic cancer through induction of ER stress and proteosome assembly

Tryptophan 2,3-dioxygenase may be a potential prognostic biomarker and immunotherapy target in cancer: A meta-analysis and bioinformatics analysis

Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model

ITGB5 promotes innate radiation resistance in pancreatic adenocarcinoma by promoting DNA damage repair and the MEK/ERK signaling pathway

Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers – current evidence and future directions

The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysis

MiR-21 and let-7 cooperation in the regulation of lung cancer

Ubiquitin-specific peptidase 10, a deubiquitinating enzyme: Assessing its role in tumor prognosis and immune response

Muramyl dipeptide-based analogs as potential anticancer compounds: Strategies to improve selectivity, biocompatibility, and efficiency

Editorial: Targeting DNA repair and the DNA damage response: Beyond the standard PI3 kinase-like kinases

AMBRA1 and its role as a target for anticancer therapy

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review